-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

613.O3.6 613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
AML, Biological, Adult, antibodies, CRS, Diseases, CML, Non-Biological, Therapies, Combinations, Elderly, Adverse Events, chemotherapy, Biological Processes, Hemoglobinopathies, Technology and Procedures, Young Adult, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , immune mechanism, molecular testing
Sunday, December 6, 2020: 2:00 PM-3:30 PM
Moderators:
Annie Im, MD, UPMC Hillman Cancer Center, University of Pittsburgh and Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Stein: Celgene Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Amgen: Consultancy; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Biotheryx: Consultancy; Syndax: Consultancy, Research Funding; Seattle Genetics: Consultancy; Abbvie: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; PTC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees.
2:00 PM

Christoph Röllig, MD, MSC1*, Björn Steffen, MD2*, Nael Alakel, MD3*, Regina Herbst, MD4*, Richard Noppeney, MD5*, Maher Hanoun, MD, PhD6*, Zdenek Racil, MD, PhD7*, Kerstin Schäfer-Eckart, MD8*, Alwin Krämer, MD9*, Andreas Neubauer, Professor Dr10, Claudia D Baldus, MD11*, Christoph Schliemann, Prof., MD12*, Martin Kaufmann, MD13, Jolana Mertova14*, Edgar Jost15*, Dirk Niemann, MD16*, Jan Novak17*, Stefan W Krause18*, Sebastian Scholl19,20*, Gerhard Held, Professor Dr21*, Stefani B. Parmentier22, Tomáš Szotkowski, MD, PhD23*, Pavel Zak, MD24*, Andreas Rank, PD Dr25*, Maxi Wass, MD26*, Sebastian Buske27*, Michael Kramer28*, Frank Fiebig29*, Annett Haake29*, Johannes Schetelig, MD, MSc30, Uwe Platzbecker, MD31, Christian Thiede, MD32, Carsten Müller-Tidow, MD33*, Wolfgang E. Berdel, Prof., MD12, Hubert Serve, MD, PhD34, Gerhard Ehninger, MD32, Jiri Mayer35* and Martin Bornhäuser, MD28*

1Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
2Medizinische Klinik II, Klinikum der J.W. Goethe Universität, Frankfurt am Main, Germany
3University Hospital, Dresden, Germany
4Klinikum Chemnitz, Chemnitz, DEU
5Department of Hematology, University Hospital of Essen, Essen, Germany
6Universitätsklinikum Essen, Essen, DEU
7UHKT, Prague 2, CZE
8Klinik für Innere Medizin V, Klinikum Nürnberg Nord, Nürnberg, Germany
9Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, Heidelberg, Germany
10Klinik für Innere Medizin, Schwerpunkt Hämatologie, Onkologie und Immunologie, Philipps University, Marburg, Germany
11Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
12Medizinische Klinik A, Universitätsklinikum Münster, Münster, Germany
13Abteilung für Hämatologie, Onkologie und Palliativmedizin, Robert Bosch Krankenhaus, Stuttgart, Germany
14UHKT, Prague, Czech Republic
15Department of Internal Medicine IV, Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany
16Department of Internal Medicine, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany
17University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles U, Prague, CZE
18Department of Internal Medicine V, University Hospital Erlangen, Erlangen, Germany
19Department of Hematology and Oncology, Universitätsklinikum Jena, Klinik für Innere Medizin II, Jena, Germany
20University Hospital Jena, Jena, Germany
21Department of Internal Medicine I, Westpfalz-Klinikum, Kaiserslautern, Germany
22Klinik für Hämatologie, Onkologie und Palliativmedizin, Rems-Murr-Klinikum Winnenden, Winnenden, Germany
23Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
24Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic
25Medical Clinic II, University Hospital of Augsburg, Augsburg, Germany
26Hematology and Oncology, University Hospital of Halle (Saale), Halle (Saale), Germany
27Städtisches Krankenhaus Kiel, Kiel, DEU
28Department of Hematology and Oncology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany
29Universitätsklinikum Dresden, Dresden, Germany
30Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany
31Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
32Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
33Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
34Medizinische Klinik 2, Hämatologie/Onkologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany
35University Hospital Brno, Czech Republic, Brno, CZE

2:15 PM

Huafeng Wang, MD1*, LU LIU, MD1*, Jianfeng Zhou, MD, PhD2*, Jianyong Li, MD, PhD3, Ying Lu, MD4*, Jianping Shen, MD5*, Chunyan Ji, MD6*, Tong Chen, MD, PhD7, Kang Yu, MD8*, Hanyun Ren, MD9, Yan Li, MD10*, Dengju Li, MD2*, Ying Chen, MD5*, Shaolei Zang, MD6*, Bin Liang, MD8*, Sijing Kang, MD10*, Jinghan Wang, MD, PhD1*, Wei Cheng, PhD11*, Haitao Meng, MD, PhD1*, Wen-Juan Yu1*, Yanhong Tong1*, Honghu Zhu, MD1* and Jie Jin, MD, PhD1

1Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
4Department of Hematology, the Affiliated People's Hospital to Ningbo University, Ningbo, China
5Hematology Department, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, China
6Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
7Division of Hematology, Huashan Hospital of Fudan University, Shanghai, China
8Affiliated First Hospital of WenZhou Medical College, Wenzhou, China
9Department of Hematology, Peking University First Hospital, Beijing, China
10Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China
11Zhejiang Provincial Centre for Disease Control and Prevention, Hangzhou, China

2:30 PM

Farhad Ravandi, MBBS1, Asad Bashey, MD, PhD2, Wendy Stock, MD3, James M. Foran, MD4, Raya Mawad, MD5*, Daniel Egan, MD6*, William Blum, MD7*, Allen Yang, MD, PhD8, Alessandro Pastore, MD9, Chelsea Johnson, BSN, RN8*, Shuo Zheng8*, Musa Yilmaz, MD10 and Alice S. Mims, MD11

1Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
2BMT Group of Georgia, Atlanta, GA
3Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL
4Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL
5Swedish Cancer Institute, Seattle, WA
6Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
7Winship Cancer Institute of Emory University, Atlanta, GA
8Xencor, Inc., San Diego, CA
9Translational Clinical Oncology, Novartis Institutes for BioMedical Research, East Hanover, NJ
10Department of Leukemia, MD Anderson Cancer Center, Houston, TX
11The Ohio State University Comprehensive Cancer Center, Columbus, OH

2:45 PM

Daniel A. Pollyea, MD1, Courtney D. Dinardo, MD, MSc2, Martha L. Arellano, MD3, Arnaud Pigneux, MD, PhD4*, Walter Fiedler, MD5, Marina Konopleva, MD, PhD6, David A Rizzieri, MD7, B. Douglas Smith, MD8, Atsushi Shinagawa, MD, PhD9*, Roberto M. Lemoli10, Monique Dail, PhD11*, Yinghui Duan, PhD12*, Brenda J. Chyla12, Jalaja Potluri, MD12, Jean A Ridgeway, DNP, NP-C12* and Hagop M. Kantarjian, MD13

1UCHealth University of Colorado Hospital, Denver, CO
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
4CHU Bordeaux, Bordeaux, FRA
5Hubertus Wald University Cancer Center, Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6University of Texas, MD Anderson Cancer Center, Houston, TX
7Duke University School of Medicine, Durham, NC
8Department of Oncology, Johns Hopkins Medicine, Baltimore, MD
9Department of Hematology, Hitachi General Hospital, Ibaraki, Japan
10Clinic of Hematology, Department of Internal Medicine (DiMI), Policlinico San Martino, IRCCS per l’Oncologia, University of Genoa, Genoa, Italy
11Genentech Inc., South San Francisco, CA
12AbbVie Inc., North Chicago, IL
13Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

3:00 PM

Maël Heiblig, MD1*, Hélène Labussière, MD2*, Marie Virginie Larcher, MD3*, Gaelle Fossard, MD4*, Marie Balsat, MD4*, Sophie Ducastelle, MD2*, Sandrine Loron, MD2*, Sandrine Hayette, PhD5*, Sarah Huet6*, Pierre Sujobert, MD, PhD7*, Fiorenza Barraco, MD8*, Xavier Thomas, MD, PhD9, Alice Marceau10*, Delphine Lebon, MD11*, Laure Goursaud12*, Isabelle Plantier, MD13*, Laure Stalnikiewich14*, Cecile Frimat15*, Nathalie Cambier16*, Nicolas Duployez, PharmD, PhD17*, Herve Ghesquieres, MD, PhD18* and Claude Preudhomme, MD, PhD19

1Centre Hospitalier Lyon Sud, Lyon, FRA
2Hematology department 1 G, Centre Hospitalier Lyon Sud, Pierre Benite, France
3Lyon Sud Hospital, Pierre Bénite, France
4Hematology, Centre Hospitalier Lyon Sud, Pierre Benite, France
5Centre Hospitalier Lyon Sud, Pierre Benite, FRA
6Centre Hospitalier Universitaire de Lyon, Lyon, France
7Laboratory of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France
8Centre Hospitalier Universitaire Lyon Sud, Lyon, France
9Department of Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, Lyon, France
10Centre de Biologie-Pathologie, CHU Lille, Lille, France
11CHU Amiens Picardie Hôpital, Amiens, France
12Service des Maladies du sang, CHRU Lille, Lille, France
13Service d'hématologie clinique, CH Roubaix, Roubaix, France
14Département Hématologie, CH Lens, Lens, France
15CHRU Lille, Lille, France
16Cytologie, CH Valenciennes, Valencienne, France
17Laboratory of Hematology, Centre Hospitalier Universitaire Lille, Lille, France
18Department of Hematology, Centre Hospitalier Lyon-Sud, University Claude Bernard Lyon 1, Pierre Benite, France
19ALFA Group, Paris, France

3:15 PM

Muhned Alhumaid, MD1,2, Georgina S. Daher-Reyes, MD3*, Aaron D Schimmer, MD, PhD4, Andre C. Schuh3, Anne Tierens, MD, PhD5, Caroline J McNamara, MBBS3, Dawn Maze, MD, FRCPC, MSc6, Igor Nicolas Novitzky-Basso, MD, PhD, MRCP, FRCPath1, Karen W.L. Yee, MD3, Mark D. Minden3, Steven M Chan, MD, PhD4, Tracy Murphy, MD, FRCP, FRCPath3, Vikas Gupta, MD, FRCP, FRCPath3, Dennis Dong Hwan Kim, MD1 and Hassan Sibai, MBBS3*

1Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
2King Saud Medical City, Riyadh, Saudi Arabia
3Leukemia Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
4Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
5Princess Margaret Cancer Centre, Department of Pathology, University Health Network, University of Toronto, Toronto, ON, Canada
6Leukemia Program, Division of Medical Oncology and Hematology, The Ottawa Hospital, Toronto, ON, Canada

*signifies non-member of ASH